Literature DB >> 19556339

Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens.

Keiichi Ito1, Hidehiko Yoshii, Junichi Asakuma, Akinori Sato, Akio Horiguchi, Makoto Sumitomo, Masamichi Hayakawa, Tomohiko Asano.   

Abstract

OBJECTIVE: Renal cell carcinoma (RCC) with a high-nucleolar-grade component is considered to be an aggressive type of tumor. In the present study, we evaluated the impact of the presence of the worst-nucleolar-grade component and also tried to determine predictors for recurrence and prognosis in patients with the worst grade component.
METHODS: We evaluated 314 patients with RCC. A three-graded system was used for nucleolar grading, the patients were classified into four groups according to the presence of the worst nucleolar grade (Grade 3) and the occupancy of each grade, and clinicopathological factors and clinical outcomes were compared. In patients of Grade 3 components (Groups 1 and 2), factors influencing on prognosis and recurrence were evaluated by multivariate analysis.
RESULTS: There was no significant difference in clinicopathological factors between Group 1 (with Grade 3-dominant tumors) and Group 2 (with tumors in which Grade 1 or 2 was dominant and there were Grade 3 components). Neither did cause-specific survival or recurrence-free survival differ significantly between those two groups. In multivariate analysis, only distant metastasis was an independent predictor for prognosis in all patients with Grade 3 components. Moreover, an elevated C-reactive protein (CRP) level (>or=1 mg/dl) was the only independent predictor of recurrence in N0M0 patients.
CONCLUSIONS: Regardless of dominancy, the presence of the worst grade component has a significant clinical impact in RCC patients. N0M0 patients whose RCC has worst-grade components but whose CRP levels are <1 are expected to have longer recurrence-free intervals and to survive longer than those whose CRP levels are higher.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556339     DOI: 10.1093/jjco/hyp068

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

1.  Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis.

Authors:  Shinsuke Hamada; Keiichi Ito; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  Mol Clin Oncol       Date:  2014-09-29

2.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

3.  Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma.

Authors:  Keiichi Ito; Kenji Seguchi; Hideyuki Shimazaki; Eiji Takahashi; Shinsuke Tasaki; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Tomohiko Asano
Journal:  Oncol Lett       Date:  2014-11-04       Impact factor: 2.967

Review 4.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  On detection of periodicity in C-reactive protein (CRP) levels.

Authors:  Mohsen Dorraki; Anahita Fouladzadeh; Stephen J Salamon; Andrew Allison; Brendon J Coventry; Derek Abbott
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.